Pediatric non-alcoholic fatty liver disease: New insights and future directions

doi:10.4254/wjh.v6.i4.217

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 4

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9100)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

940

WORD

342

HTML

5743

Figures (1-1)

271

Tables (1-1)

139

Sum=7435

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

921

Download

744

Sum=1665

Apr 27, 2014 (publication date) through Apr 30, 2024

Times Cited of This Article

Times Cited (42)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Apr 27, 2014; 6(4): 217-225
Published online Apr 27, 2014. doi: 10.4254/wjh.v6.i4.217

Full Size Figure Download Figure

Figure 1 Risk factors for non-alcoholic fatty liver disease development. In this figure, all risk factors for non-alcoholic fatty liver disease (NAFLD) are summarized. We divided the risk factors in modifiable and not modifiable. Among not modifiable risk factors we listed PNPLA3 rs738409, but as underlined in the text, the weight loss can modify the capacity of PNPLA3 polymorphism to lead to hepatic steatosis. PNPLA3: Patatin like phospholipase 3 gene; GCKR: Glucokinase regulatory protein; FDFT1: Farnesyl-diphosphate farnesyltransferase 1; NCAN: Neurocan; PPP1R3B: Protein phosphatase 1 regulatory subunit 3B; LYPLAL1: Lysophospholipase-like 1; GC: Group-specific component; LCP1: Lymphocyte cytosolic protein-1; LPPR4: Lipid phosphate phosphatise-related protein type 4; SLC38A8: Solute carrier family 38 member 8; APOC3: Apolipoprotein C3 gene; SAMM50: Sorting and assembly machinery component; PARVB: Parvin beta.

Citation: Marzuillo P, Giudice EMD, Santoro N. Pediatric non-alcoholic fatty liver disease: New insights and future directions. World J Hepatol 2014; 6(4): 217-225
URL: https://www.wjgnet.com/1948-5182/full/v6/i4/217.htm
DOI: https://dx.doi.org/10.4254/wjh.v6.i4.217